Perrigo, the drugs company that bought out Elan, has announced plans to consolidate more of its operations here.
The company relocated to Ireland after the $8.6 billion Elan deal in 2014.
It said it was taking immediate steps to consolidate its supply chain and procurment activities into a centre of global excellence.
"Our acquisition of Elan in 2014 was the first step towards growing our footprint in the country and has been high on the agenda ever since. Ireland, and the talent that exists there will be a huge asset as we continue to grow," commented the company's chief executive Joe Papa.
"Today’s announcement is in line with our plan to operate much of our global infrastructure from Ireland, which is an integral part of our expansion in Europe and Asia," Mr Papa said.
"Supply chain and procurement management activities will be part of a new global centre of excellence based in Ireland and it is likely that we will also acquire a distribution facility in Ireland in the near term," he added.
errigo also said it would lay off 6% of its global workforce and buy back shares worth $2 billion to boost earnings, as the generic drug maker looks to convince investors to rebuff Mylan hostile bid. This would equate to about 800 jobs.
Mylan, which first made a bid for Perrigo in April, went hostile in September, offering $75 in cash and 2.3 of its shares for each Perrigo share held.
Under Irish laws, Mylan has to secure at least 80% of Perrigo shares for the deal to go through. Perrigo shareholders have until November 13 to accept Mylan's offer.
The Perrigo CEO Joe Papa said the company was not against deals and was willing to consider opportunities.
"We just happen to think the deal in front of us today is a bad deal," Papa told Reuters. "If someone came in with a cash offer or an appropriate premium to our standalone price, we'd certainly be open to that."
Perrigo's board, which is restricted by Irish laws from blocking the deal, has repeatedly urged shareholders not to accept Netherlands-based Mylan's offer.
